Oosting SF, van der Veldt AAM, Fehrmann RSN, Bhattacharya A, van Binnendijk RS, GeurtsvanKessel CH, Dingemans AC, Smit EF, Hiltermann TJN, den Hartog G, Jalving M, Westphal TT, de Wilt F, Ernst SM, Boerma A, van Zijl L, Rimmelzwaan GF, Kvistborg P, van Els CACM, Rots NY, van Baarle D, Haanen JBAG, de Vries EGE
Treatment with chemotherapy and immunotherapy at the time of coronavirus disease 2019 (COVID-19) vaccination may result in inadequate humoral responses. We and others have demonstrated that a third vaccination increases serum severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific antibody concentration, but little is known about long-term antibody concentrations and breakthrough infections in these patients. Here, we report the 18-month data of the prospective multicenter VOICE trial (NCT04715438) of COVID-19 vaccination in patients treated for solid tumors with immunotherapy (cohort B), chemotherapy (cohort C), or chemoimmunotherapy (cohort D) compared with controls (cohort A). In the trial, participants received two mRNA-1273 vaccinations (100 μg intramuscularly) 4 weeks apart and a third vaccination if the initial response was inadequate. All participants had access to additional COVID-19 messenger RNA (mRNA) vaccinations in the national vaccination program.
